NASDAQ:NMTR 9 Meters Biopharma (NMTR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About 9 Meters Biopharma Stock (NASDAQ:NMTR) Get 9 Meters Biopharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume800 shsAverage Volume315,915 shsMarket Capitalization$1.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview 9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel biologic therapies for gastrointestinal, liver and immune-mediated diseases. The company’s lead candidate, GMCT02, is being evaluated in a Phase 2 clinical trial for ulcerative colitis. Beyond GMCT02, 9 Meters Biopharma’s pipeline includes additional antibody-based and immunomodulatory programs targeting inflammatory bowel disease, cholestatic liver disease and other conditions with high unmet medical need. 9 Meters Biopharma employs a lean development model, in-licensing product candidates from academic and philanthropic partners and advancing them through clinical development. Its research strategy emphasizes targeted immune regulation and tissue-specific delivery to address the underlying pathophysiology of chronic gastrointestinal disorders. The company collaborates with leading clinical investigators and academic centers to conduct its trials across North America. Headquartered in Vancouver, British Columbia, with additional offices in Boston, Massachusetts, 9 Meters Biopharma was formed in 2021 following a strategic merger and subsequent public listing on NASDAQ. The company is led by Chief Executive Officer Gregory M. Postel, who has over two decades of experience in biotechnology leadership and corporate development. 9 Meters Biopharma continues to expand its footprint through both internal discovery efforts and external licensing partnerships aimed at bringing new therapies to patients worldwide.AI Generated. May Contain Errors. Read More Receive NMTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NMTR Stock News HeadlinesEnergy firms likely to miss smart meter deadline, warns Which?December 14, 2023 | bbc.comBDeal reached to sell some assets of bankrupt Raleigh firmNovember 8, 2023 | bizjournals.comFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 16 at 1:00 AM | Porter & Company (Ad)9 Meters Biopharma, Inc. (NMTRQ)November 7, 2023 | finance.yahoo.com9 Meters Biopharma Inc (NMTRQ)October 17, 2023 | investing.com9 Meters Biopharma (OTC: NMTR.Q)August 16, 2023 | fool.comRaleigh firm joins worrying trend of bankruptcies for drugmakersJuly 18, 2023 | bizjournals.comDrug developer 9 Meters Biopharma files for bankruptcy protectionJuly 18, 2023 | reuters.comSee More Headlines NMTR Stock Analysis - Frequently Asked Questions How were 9 Meters Biopharma's earnings last quarter? 9 Meters Biopharma, Inc. (NASDAQ:NMTR) issued its quarterly earnings data on Monday, November, 15th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.26. When did 9 Meters Biopharma's stock split? 9 Meters Biopharma's stock reverse split on Tuesday, October 18th 2022.The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of 9 Meters Biopharma? Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 9 Meters Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that 9 Meters Biopharma investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), SNDL (SNDL), NIO (NIO), Advanced Micro Devices (AMD) and Alibaba Group (BABA). Company Calendar Last Earnings11/15/2021Today5/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NMTR CIK1551986 Webwww.9meters.com Phone(919) 275-1933FaxN/AEmployees20Year Founded2020Profitability EPS (Trailing Twelve Months)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-584.97% Return on Assets-159.45% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / BookN/AMiscellaneous Outstanding Shares14,336,000Free Float13,992,000Market Cap$1.04 million OptionableNo Data Beta1.36 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:NMTR) was last updated on 5/16/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
